AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

The requested reference [d7c9860cbe9c547a1e943584b86b48dd1e5473ff] no longer exists in our database. It has been replaced by the current reference: [51c632aeff900d42c712da0b3be5c378408c7bb8]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).
Epistemonikos ID: 9329a89cb4cda2552a3318b22767adb267ba986e
First added on: Nov 01, 2024